Cover image of the article: Helicobacter pylori and Serum Magnesium Level in Hemodialysis Patients

Image Credit:Jundishapur J Microbiol

Helicobacter pylori and Serum Magnesium Level in Hemodialysis Patients

Authors

Hamid Nasri1,*
1Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, IR Iran
*Corresponding Author: Corresponding author: Hamid Nasri, Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, IR Iran. Tel: +98-3112208081, Fax: +98-3112235043, E-mail: Email: hamidnasri@med.mui.ac.ir

Jundishapur Journal of Microbiology:Vol. 7, issue 2; e11095
Published online:Feb 10, 2014
Article type:Letter
Received:Mar 12, 2013
Accepted:Apr 29, 2013
How to Cite:Nasri H. Helicobacter pylori and Serum Magnesium Level in Hemodialysis Patients. Jundishapur J Microbiol. 2014;7(2):e11095. doi: https://doi.org/10.5812/jjm.11095

Dear editor,
To understand, the aggravating factors of Helicobacter pylori in chronic renal failures, especially patients under treatment of dialysis, we conducted a research on 44 hemodialysis patients. At this study, we observed a significant positive correlation of anti-Helicobacter antibody with serum magnesium. The results of this investigation suggested the association of serum magnesium with the H. pylori infection (1). For a better investigation, we conducted another investigation on 94 type 2 diabetic patients who had a mean creatinine clearance of 62 ± 23 mL/min. In the second study, there was no significant correlation between serum anti-H. pylori specific antibody titer and serum magnesium level (2). It is obvious that magnesium ion acquisition is essential for H. pylori (1). We speculated that, the elevated serum magnesium level in hemodialysis patients and its higher concentration in the gastric mucosa may improve the gastric colonization of H. pylori in hemodialysis patients, but not in patients with various stages of kidney insufficiency who were not undergone dialysis yet (1, 2). To the best of our knowledge, these are the sole studies on the association of serum magnesium level and H. pylori in renal disease patients. Gastric complications are common in patients who underwent hemodialysis (3), and H. pylori infection is thought to have an important role in gastrointestinal disease in these patients (4-9), on the other hand magnesium is mainly excreted by kidney and magnesium metabolism is perturbed in patients with chronic kidney disease (10-14). Thus more studies are needed to prove the association of serum magnesium level and H. pylori infection in hemodialysis and finding the clinical relevance of our results.

Footnotes

  • Implication for health policy/practice/research/medical education:Gastric complications are common in hemodialysis patients, and H. pylori infection is found to have an important role in causing gastrointestinal disease in these patients. On the other hand, magnesium is mainly excreted by kidney and magnesium metabolism has deficiencies in chronic kidney disease. The association of anti-Helicobacter IgG antibody and serum magnesium level in hemodialysis patients needs to be proved in larger studies.

  • Financial disclosureThe author declared no competing of interests.

References

  • 1.
    Nasri H. Helicobacter pylori infection and its relationship to plasma magnesium in hemodialysis patients. Bratisl Lek Listy. 2007;108(12):506-9. [PubMed ID: 18309640].
  • 2.
    Baradaran A, Nasri H. Helicobacter pylori specific IgG antibody and serum magnesium in type-2 diabetes mellitus chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2011;22(2):282-5. [PubMed ID: 21422626].
  • 3.
    Jalalzadeh Mojgan, Ghadiani Mohammad Hassan, Mousavinasab Nouraddin. Association between helicobacter pylori infection and body mass index, before and after eradication of infection in hemodialysis batients. J Nephropathol. 2012;1(3):170-176. https://doi.org/10.5812/nephropathol.8115.
  • 4.
    Assadi Farahnak. The epidemic of pediatric chronic kidney disease: the danger of skepticism. J Nephropathol. 2012;1(2):61-64. https://doi.org/10.5812/jnp.7445.
  • 5.
    Gheissari Alaleh, Hemmatzadeh Saeedeh, Merrikhi Alireza, Fadaei Tehrani Sharareh, Madihi Yahya. Chronic kidney disease in children: A report from a tertiary care center over 11 years. J Nephropathol. 2012;1(3):177-182. https://doi.org/10.5812/nephropathol.8119.
  • 6.
    Gheissari Alaleh, Mehrasa Pardis, Merrikhi Alireza, Madihi Yahya. Acute kidney injury: A pediatric experience over 10 years at a tertiary care center. J Nephropathol. 2012;1(2):101-108. https://doi.org/10.5812/nephropathol.7534.
  • 7.
    Kari Jameela. Epidemiology of chronic kidney disease in children. J Nephropathol. 2012;1(3):162-163. https://doi.org/10.5812/nephropathol.8113.
  • 8.
    Rostaing L], Izopet J, Kamar N. Hepatitis C virus infection in nephrology patients. J Nephropathol. 2013;2(4):217-233.
  • 9.
    Sahni Nancy, Gupta Krishan L. Dietary antioxidents and oxidative stress in predialysis chronic kidney disease patients. J Nephropathol. 2012;1(3):134-142. https://doi.org/10.5812/nephropathol.8108.
  • 10.
    Kanbay M, Goldsmith D, Uyar ME, Turgut F, Covic A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010;29(3):280-92. [PubMed ID: 20090315]. https://doi.org/10.1159/000276665.
  • 11.
    Nasri Hamid, Rafiean-Kopaie Mahmoud. Significant association of serum H. pylori IgG antibody titer with kidney function in renal transplanted patients. J Ren Inj Prev. 2013;2(1):23-25.
  • 12.
    Pickering JW, Endre ZH. The definition and detection of acute kidney injury. J Ren Inj Prev. 2014;3(1):21-25.
  • 13.
    Solati Mehrdad, Mahboobi Hamid-Reza. Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients. J Nephropathol. 2012;1(3):123-125. https://doi.org/10.5812/nephropathol.8106.
  • 14.
    Tamadon MR, Saberi Far M, Soleimani A, Ghorbani R, Semnani V, Malek F, et al. Evaluation of noninvasive tests for diagnosis of Helicobacter pylori infection in hemodialysis patients. J Nephropathol. 2013;2(4):249-253.

Copyright

Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Similar Articles

31
Jan
2011
Prevalence of Helicobacter pylori in long-term dialysis patients

Prevalence of Helicobacter pylori in long-term dialysis patients

Mojgan Jalalzadeh1,
Fatemeh Mirzamohamadi,
Paria Zargham1

Jalalzadeh1 M, Mirzamohamadi F, Zargham1 P. Prevalence of Helicobacter pylori in long-term dialysis patients. Nephro-Urol Mon. 2011;3(1):. doi:

9
Jul
2025
The Course of Helicobacter pylori Infection in Pediatric Patients Undergoing Kidney Transplantation

The Course of Helicobacter pylori Infection in Pediatric Patients Undergoing Kidney Transplantation

Azizollah Yousefi,
Nahid Rahimzadeh,
Rozita Hosseini,
Elahe Norouzi

Yousefi A, Rahimzadeh N, Hosseini R, Norouzi E. The Course of Helicobacter pylori Infection in Pediatric Patients Undergoing Kidney Transplantation. Arch Pediatr Infect Dis. 2025;13(4):e159057. doi: https://doi.org/10.5812/apid-159057

31
Dec
2025
Nutritional Status of Children Infected with Helicobacter pylori with or Without Gastrointestinal Symptoms

Nutritional Status of Children Infected with Helicobacter pylori with or Without Gastrointestinal Symptoms

Chunpeng Chang,
Yuanda Zhang,
Qingwei Dong,
Mei-ying Wang,
Jing Bi

Chang C, Zhang Y, Dong Q, Wang M, Bi J. Nutritional Status of Children Infected with Helicobacter pylori with or Without Gastrointestinal Symptoms. Inn J Pediatr. 2025;35(6):e161946. doi: https://doi.org/10.5812/ijpediatr-161946

20
Jun
2012
Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients

Mojgan Jalalzadeh,
Morteza Nazarian,
Jamshid Vafaeimanesh,
Fatemeh Mirzamohammadi

Jalalzadeh M, Nazarian M, Vafaeimanesh J, Mirzamohammadi F. Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients. Nephro-Urol Mon. 2012;4(3):571-577. doi: https://doi.org/10.5812/numonthly.2794

24
Dec
2016
Serum Levels of Intact Parathyroid Hormone, Calcium, and Phosphorus and Risk of Mortality in Hemodialysis Patients

Serum Levels of Intact Parathyroid Hormone, Calcium, and Phosphorus and Risk of Mortality in Hemodialysis Patients

Tayebeh Soleymanian,
Neda Nikzad,
Alireza Mahjoub,
Hassan Argani,
Shokoofe Saavaj

Soleymanian T, Nikzad N, Mahjoub A, Argani H, Saavaj S. Serum Levels of Intact Parathyroid Hormone, Calcium, and Phosphorus and Risk of Mortality in Hemodialysis Patients. Nephro-Urol Mon. 2017;9(1):e42569. doi: https://doi.org/10.5812/numonthly.42569

More by these authors

Hamid NasriPubMedScholar
Share
Cited by
Metrics